Schizophrenia trials have been too small, short and exclusionary, leaving the most disabled patients under-represented and key outcomes neglected. Future research should match the illness burden through sustained funding, representative recruitment, multidomain assessment, and adaptive, platform and SMART designs that test treatments efficiently and produce evidence relevant to patients' lives.
Beck et al. (2026) studied this question.